<DOC>
	<DOCNO>NCT00730483</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Infusing doxorubicin bead liver , block blood flow tumor , may keep doxorubicin near tumor kill tumor cell . PURPOSE : This clinical trial study side effect doxorubicin bead see well work treat patient unresectable liver metastasis neuroendocrine tumor .</brief_summary>
	<brief_title>Doxorubicin Beads Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To gather preliminary data determine feasibility randomize study patient unresectable hepatic neuroendocrine metastasis use PVA microporous hydrospheres/doxorubicin hydrochloride . OUTLINE : A catheter place right left hepatic artery . Patients unifocal tumor catheter microcatheter place selectively 2nd 3rd order branch right leave hepatic artery closer proximity tumor . PVA microporous hydrospheres/doxorubicin hydrochloride mixture inject delivery area . Patients less 75 % necrosis 1 month undergo second ( possibly third month later ) chemoembolization . After completion study therapy , patient follow 1 month , every 2 month 1 year , every 3 month 1 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis hepatic neuroendocrine metastasis suitable radical therapy ( e.g. , resection liver transplantation ) Histologically proven neuroendocrine tumor Tumors hypervascular base visual estimation investigator Predominant liver disease , extrahepatic disease exclusion No predominant extrahepatic liver disease No significant lifethreatening extrahepatic disease , judgment physician Recentinterval progression hepatic liver metastases No diffuse hepatic neuroendocrine metastasis define massive illdefined tumor involvement measure &gt; 90 % tumor burden Exclusion criterion : Clinically evident ascites ( radiographic find trace ascites image acceptable ) Complete occlusion entire portal venous system Evidence cirrhosis portal hypertension Vascular resistance peripheral feeding artery preclude passage PVA microporous hydrospheres/doxorubicin hydrochloride PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Must preserve liver function ( ChildPugh class AB ) without significant liver decompensation No advance liver disease ( e.g. , ChildPugh C class active gastrointestinal bleeding , encephalopathy , ascites [ trace ascites acceptable ] ) , meet follow criterion : Bilirubin &gt; 3 mg/dL AST , ALT , alkaline phosphatase &gt; 5 time upper limit normal Serum creatinine &gt; 2.0 mg/dL Albumin ≤ 2.0 g/dL No vascular anatomy blood precludes catheter placement embolus injection No presence artery supply lesion large enough accept PVA microporous hydrospheres/doxorubicin hydrochloride No collateral vessel pathway potentially endanger normal territory embolization No feeding arteries small distal branch emerge Not pregnant Exclusion criterion : See Disease Characteristics Another active primary tumor Any contraindication hepatic embolization procedure , include follow : Portosystemic shunt Hepatofugal blood flow Impaired clot test ( i.e. , platelet count &lt; 50,000/mm³ , INR ≥ 1.8 , PTT ≥ 39 second ) Renal failure Severe peripheral vascular disease preclude catheterization Any contraindication doxorubicin hydrochloride administration ( i.e. , serum bilirubin &gt; 5 mg/dL leukocyte count &lt; 1,500 cells/mm³ ) Allergy contrast medium Intolerant occlusion procedure Presence end artery lead directly cranial nerve Presence likely onset hemorrhage Presence severe atheromatous disease PRIOR CONCURRENT THERAPY : Exclusion criterion : Prior anticancer therapy hepatic neuroendocrine metastasis , except previous surgical therapy Any continue complication prior cancer therapy improve resolve prior 21 day start treatment , investigator determines continue complication compromise safety patient treatment PVA microporous hydrospheres/doxorubicin hydrochloride Presence patent extratointracranial anastomosis shunt Use PVA microporous hydrospheres/doxorubicin hydrochloride follow application : Embolization largediameter arteriovenous shunt Pulmonary arterial vasculature Any vasculature use PVA microporous hydrospheres/doxorubicin hydrochloride could pass directly internal carotid artery abovelisted vessel Concurrent enrollment another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>islet cell carcinoma</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
</DOC>